Magazine article Science News

Fatal Flaw? Antibleeding Drug Faces New Safety Questions

Magazine article Science News

Fatal Flaw? Antibleeding Drug Faces New Safety Questions

Article excerpt

A drug commonly used to slow bleeding during heart surgery increases a patient's risk of dying during the next 5 years, a new study suggests.

U.S. heart surgeons have used the drug, called aprotinin, for 14 years. But last year, researchers reported that people receiving it had heightened risks of kidney problems, heart attack, and stroke. Those findings prompted the U.S. Food and Drug Administration to change the labeling on aprotinin to limit its use to coronary-bypass surgery patients at high risk of blood loss.

In the new study, researchers analyzed the risk of death from any cause for 3,876 heart-bypass surgery patients during the first 5 years after their operations. Some patients had received aprotinin during surgery, while others got one of two other drugs that are sometimes used during coronary-bypass surgery but have been approved to suppress bleeding only under other circumstances. Patients who had received no antibleeding agent served as a comparison group.

The people who had received aprotinin were about 60 percent more likely to die within 5 years than were the patients who had gotten no drug. In contrast, mortality among people who received one of the other drugs was no higher than that in the comparison group, the scientists report in the Feb. 7 Journal of the American Medical Association (JAMA).

The alternative drugs--aminocaproic acid (Amiear) and tranexamic acid (Cyklokapron)--are less expensive than aprotinin and just as effective at decreasing bleeding during bypass surgery, says study coauthor Dennis T. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.